fibrosis

Boehringer Ingelheim advances potential first-in-class IL-11 inhibitor to Phase II Clinical Research in Idiopathic Pulmonary Fibrosis

Not intended for US and UK audiences BI 765423 has been developed to target IL-11, a key driver of fibrosis…

2 days ago

Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted Therapeutics in Solid Tumors and Fibrosis

Company has built one of the largest proprietary extracellular matrix (ECM) datasets spanning fibrosis and solid tumors January 08, 2026…

1 week ago

JASCAYD (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China

The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five…

1 month ago

BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis

The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift…

2 months ago